Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612001125819
Ethics application status
Approved
Date submitted
13/08/2012
Date registered
22/10/2012
Date last updated
22/10/2012
Type of registration
Retrospectively registered
Titles & IDs
Public title
Prospective evaluation of responses to hypoglycaemia in newly diagnosed young patients with type 1 diabetes: does intensive diabetes management prevent loss of glucagon response and hypoglycaemia awareness?
Query!
Scientific title
Prospective evaluation of responses to hypoglycaemia in newly diagnosed young patients with type 1 diabetes: does intensive diabetes management prevent loss of glucagon response and hypoglycaemia awareness?
Query!
Secondary ID [1]
273359
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1125-7693
Query!
Trial acronym
IMS
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Type 1 Diabetes Mellitus
279136
0
Query!
Condition category
Condition code
Metabolic and Endocrine
279327
279327
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The treatment group is treated with continuous subcutaneous insulin injection (CSII) starting at diagnosis of type 1 diabetes. The dose will vary from patient to patient and over time. Individual rates and factors will be calculated and adjusted for basal rate, insulin sensitivity and insulin:carbohydrate ratio for meals.
Participants of the treatment group will be in contact with the diabetes team as follows: Diabetes Nurse Educator (DNE) once weekly for first the 5 months, once every 2 weeks for the next 4 months and once per month until 18 months post diagnosis. Quality of life assessment will be at diagnosis, 3, 6,12 and 18 months later. Dietetic assessment will be at 1 and 12 months.
The counter regulatory response (glucagon, cortisol, adrenaline, growth hormone) to hypoglycaemia and c-peptide release will be assessed at three time points (6-11 weeks, 9 and 18 months). These visits include a hyperinsulinaemic clamp study, an arginine stimulation test and a meal challenge (standardised carbohydrate and protein-rich meal).
We used the following questionnaires:
- Hypoglycaemia: Hypoglycaemia Awareness Questionnaire/ modified Clarke's questionnaire (parent and child)
- Dietetic Questionnaires: A nutrition quiz was developed by the dieticians, one for pumpers and one for MDI patients. Each quiz consisted of 4 multi-part questions, with each question asking about a different nutrition knowledge area.
- Psychology Questionnaires
Child Questionnaires
- Strengths and Difficulties Questionnaire (S11-17, Robert Goodman 2002)
- Diabetes Quality of life for youth
- Self-efficacy for Diabetes Scale (SED)
- Diabetes Attitude Questionnaire (Att 19)
- McMasters Family Assessment Device
Parental Questionnaires
- Strengths and Difficulties Questionnaire (P11-17, Robert Goodman 2002)
- Diabetes Management Scale for Parents.
Query!
Intervention code [1]
283881
0
Treatment: Devices
Query!
Intervention code [2]
285289
0
Treatment: Drugs
Query!
Comparator / control treatment
Group on multiple daily insulin injections (MDI) as per departmental guidelines.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
287540
0
1. Counter regulatory hormones
Query!
Assessment method [1]
287540
0
Query!
Timepoint [1]
287540
0
Analysis during hypoglycaemic insulin clamps at three time points:
1. 6-11 weeks; 2. 9 months; 3. 18 months.
Query!
Primary outcome [2]
287541
0
2. Glycaemic control
Query!
Assessment method [2]
287541
0
Query!
Timepoint [2]
287541
0
HbA1c for CSII group 6 weekly; MDI group: 3 monthly until 18 months post diagnosis of type 1 diabetes.
Regular recording of episodes of hypoglycaemia at educator/ doctor appointments until 18 months post diagnosis of type 1 diabetes.
Query!
Secondary outcome [1]
298354
0
3. Quality of life assessment
Query!
Assessment method [1]
298354
0
Query!
Timepoint [1]
298354
0
Questionnaires at diagnosis, 3, 6,12,18 months.
Child Questionnaires
- Strengths and Difficulties Questionnaire (S11-17, Robert Goodman 2002)
- Diabetes Quality of life for youth
- Self-efficacy for Diabetes Scale (SED)
- Diabetes Attitude Questionnaire (Att 19)
- McMasters Family Assessment Device
Parental Questionnaires
- Strengths and Difficulties Questionnaire (P11-17, Robert Goodman 2002)
- Diabetes Management Scale for Parents
Query!
Secondary outcome [2]
298355
0
4. Dietetic assessment
Query!
Assessment method [2]
298355
0
Query!
Timepoint [2]
298355
0
Questionnaires at 1,12 months.
A nutrition quiz was developed by the dieticians, one for pumpers and one for MDI patients. Each quiz consisted of 4 multi-part questions, with each question asking about a different nutrition knowledge area.
Query!
Eligibility
Key inclusion criteria
Type 1 Diabetes
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
16
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Existing psychopathology
Existing Family Stressors
Requiring interpreter
Existing seizure disorder
Any participant who has a hypoglycaemic seizure or is subsequently diagnosed with a seizure disorder will be withdrawn from the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Recruitment on day 2 post diagnosis of type 1 diabetes. Randomisation using a sealed opaque envelope chosen in random order (Altman et al).
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a sealed opaque envelope chosen in random order (Altman et al).
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
15/07/2004
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
285646
0
Charities/Societies/Foundations
Query!
Name [1]
285646
0
Juvenile Diabetes Research Foundation (JDRF)
Query!
Address [1]
285646
0
PO Box 481
Osborne Park WA 6917
Query!
Country [1]
285646
0
Australia
Query!
Primary sponsor type
Government body
Query!
Name
National Health and Medical Research Council (NHMRC)
Query!
Address
GPO Box 1421
Canberra ACT 2601
Query!
Country
Australia
Query!
Secondary sponsor category [1]
284481
0
None
Query!
Name [1]
284481
0
Query!
Address [1]
284481
0
Query!
Country [1]
284481
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
286324
0
Princess Margaret Hospital for Children Ethics Committee
Query!
Ethics committee address [1]
286324
0
Ethics Committee Secretary Women's and Children's Health Service GPO Box D184 PERTH WA 6840
Query!
Ethics committee country [1]
286324
0
Australia
Query!
Date submitted for ethics approval [1]
286324
0
28/04/2004
Query!
Approval date [1]
286324
0
15/07/2004
Query!
Ethics approval number [1]
286324
0
1015/EP
Query!
Summary
Brief summary
A major contributing factor to the vulnerability of patients with T1DM to hypoglycaemia is a defective counter-regulatory hormone response. It has been proposed that the loss of the glucagon response to hypoglycaemia is linked to the loss of the c-peptide. The aim of the study was to investigate whether tight glycaemic control from diagnosis can preserve the glucagon response to hypoglycaemia. Newly diagnosed adolescents with T1DM were randomly assigned to pump therapy with intensive management or MDI. Hypoglycaemic hyperinsulinaemic clamp studies were performed at 6 weeks, 9 months and 18 months after diagnosis. At each study session, glucagon response following 40 mins of hypoglycaemia and after arginine stimulation was assessed, as well as c-peptide response to a meal challenge. HbA1c was measured 3 monthly. To analyse surrounding factors questionnaires on quality of life and diet were completed as well.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33374
0
Query!
Address
33374
0
Query!
Country
33374
0
Query!
Phone
33374
0
Query!
Fax
33374
0
Query!
Email
33374
0
Query!
Contact person for public queries
Name
16621
0
Assoc Prof Elizabeth A Davis
Query!
Address
16621
0
Princess Margaret Hospital
Department of Endocrinology and Diabetes
Roberts Road
Subiaco, WA 6008
Query!
Country
16621
0
Australia
Query!
Phone
16621
0
+61893408090
Query!
Fax
16621
0
+61893408605
Query!
Email
16621
0
[email protected]
Query!
Contact person for scientific queries
Name
7549
0
Assoc Prof Elizabeth A Davis
Query!
Address
7549
0
Princess Margaret Hospital
Department of Endocrinology and Diabetes
Roberts Road
Subiaco, WA 6008
Query!
Country
7549
0
Australia
Query!
Phone
7549
0
+61893408090
Query!
Fax
7549
0
+61893408605
Query!
Email
7549
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF